Recordati Calls 2026 Shareholders’ Meeting to Approve Accounts, Incentive Plan and New Financing Powers

Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) has provided an announcement.

Recordati has convened an ordinary and extraordinary shareholders’ meeting for 29 April 2026, to be held without physical attendance and with voting exercised exclusively via an appointed representative. Shareholders will vote on approval of the 2025 financial statements and profit allocation, renewal of the Board of Statutory Auditors and their remuneration, the remuneration policy report, a new 2026–2028 performance share incentive plan, and a treasury share buyback and disposal authorization.

In the extraordinary session, shareholders will be asked to delegate to the Board of Directors the power to issue bonds, including convertible bonds, and to increase share capital up to 10% of existing capital, requiring an amendment to the company’s by-laws. These measures, if approved, would enhance Recordati’s financial and capital-raising flexibility, align management incentives with long-term performance, and potentially affect capital structure and shareholder returns through buybacks and equity-linked funding options.

The most recent analyst rating on (IT:REC) stock is a Buy with a EUR57.50 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.

More about Recordati Industria Chimica e Farmaceutica SPA

Recordati Industria Chimica e Farmaceutica S.p.A. is an Italian pharmaceutical group based in Milan that develops and markets medicinal products. The company focuses on prescription pharmaceuticals and specialty treatments, operating globally with a diversified portfolio in primary care and specialty care markets.

Average Trading Volume: 329,583

Technical Sentiment Signal: Hold

Current Market Cap: €9.18B

See more data about REC stock on TipRanks’ Stock Analysis page.